WINDLASNSE8 November 2022

Windlas Biotech Limited has informed the Exchange about Investor Presentation

Windlas Biotech Limited

Reg. Off.: 40/1, Mohabewala Industrial Area Dehradun, Uttarakhand 248 110, India Tel.:+91-135-6608000-30, Fax:+91-135-6608199

Corp. Off.: 705-706, Vatika Professional Point, Sector-66, Golf Course Ext. Road, Gurgaon, Haryana 122 001, India Tel.:+91-124-2821030

CIN-L74899UR2001PLC033407

Ref No. WBL/SE/2022-2023

November 8, 2022

To Listing / Compliance Department BSE Limited Phiroze Jeejeebhoy Towers Dalal Street, Mumbai – 400 001

To Listing / Compliance Department National Stock Exchange of India Limited Exchange Plaza, C-1, Block G Bandra Kurla Complex Bandra (E), Mumbai – 400 051

BSE CODE: 543329

NSE SYMBOL: WINDLAS

Dear Sir/ Madam.

Sub: Regulation 30(6) of SEBI (LODR) Regulations, 2015

Please find enclosed herewith the Results Presentation for the Quarter and Half Year ended September 30, 2022 for your records.

Kindly take the same on record.

Thanking you,

Yours faithfully,

For Windlas Biotech Limited

Ananta Narayan Panda Company Secretary & Compliance Officer

Enc: as above

www.windlas.com

Windlas Biotech Limited Investor Presentation – November 2022

Safe Harbour

This presentation and the accompanying slides (the “Presentation”), which have been prepared by Windlas Biotech Limited (the “Company”), have been prepared solely for

information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in

connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing

detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty,

express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This

Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this

Presentation is expressly excluded.

Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively

forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions

that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international

markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and

expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks,

as well as other risks. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this

Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by

third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third party statements and projections.

Managing Director’s Message

“The company delivered a healthy growth amid various macro-economic uncertainties. The Q2 FY’23 top line grew by 15.2% YoY and H1 FY’23 grew by 11.7%. This was mainly on account of robust growth of 17% in Q2 for CDMO vertical and 47% in Q2 for Trade Generics verticals. The bottom line grew at an even faster pace registering a growth of 47%, both in Q2 and H1 FY23. The company increased its presence of chronic and sub-chronic medicines and complex generic products, since these continue to offer a large growth opportunity for both top and bottom line. Due to the cost-plus model in CDMO and higher gross margins of Trade Generics vertical the company has been able to demonstrate stable profitability despite a highly variable input costs environment linked to global supply chain volatilities. EBITDA margins expanded by around 70 bps YoY, indicating an improvement in margins despite inflationary and volatile business environment.

Mr. Hitesh Windlass

The company is using its competence to strengthen its role as a partner to its customers as opposed to just being a vendor. These efforts have ensured that the company remains a valued the first preference for various pharma companies in the diabetes, cardiological and gastro space. Our new product launches have enabled our CDMO customers in gaining a early-mover advantage in many of their core chronic therapies. We continue to enhance this value proposition by investing in new product development and enhanced just-in-time delivery.

Company's varied activities for the CDMO vertical include fresh patent expiry launches, gaining wallet share from current customers, attracting new clients, and introducing distinctive products underpinned by top-notch R&D and ongoing capex for injectables. The government’s thrust on quality will further facilitate consolidation and benefit large players like Windlas Biotech.

Windlas is experiencing excellent growth in the Domestic Trade Generics segment, which is being supported by a rapidly expanding distributor network. The trade generics space is largely underpenetrated and poses various avenues for growth.

The primary external tailwinds for the forthcoming growth phase of the Domestic Trade Generics vertical are predicted to be rising consumer demand for high-quality generics and government measures that will enhance generic adoption and reliance across India. Branding, channel expansion, new product release, and regional expansion are additional internal growth factors.

While the company has been filing numerous dossiers and making sustained efforts in the exports space, this growth is largely fag-ended and we are yet to reap the benefits of most of the work done there. Moreover, with the recent completion of the SAPHRA and EU-GMP audits which have permitted access into the newer and regulated markets, the exports vertical is primed to flourish.

The board of directors of the company have approved a share buyback program under which the company may repurchase up to Rs. 25 crores of the outstanding shares. There will be no participation from promoters in this buy back program. We at Windlas Biotech, maintain a disciplined and judicious capital allocation approach and are committed to deploy the capital thoughtfully where we believe we can create the greatest value for our shareholders 3 while at the same time growing our business and keeping the strategic reserve for the potential inorganic growth opportunities.”

Financial Performance Highlights

Quarterly Performance Highlights

Revenue

+15%

132.7

115.3

EBITDA & EBITDA Margin (%) EBITDA & EBITDA Margin (%)

13.4% 11.4%

12.1% 11.2%

Rs. Crores

+22%

16.1

13.2

d e t a d

i l

o s n o C

Q2 FY22

Q2 FY23

Q2 FY22

Q2 FY23

CDMO

Trade Generics

Exports

+17%

106.6

91.2

+37%

23.1

16.9

5.5

-54%

2.5

e u n e v e R

a c i t r e V

Q2 FY22

Q2 FY23

Q2 FY22

Q2 FY23

Q2 FY22

Q2 FY23

Half-yearly Performance Highlights

Revenue

+12%

252.7

226.2

EBITDA & EBITDA Margin (%) EBITDA & EBITDA Margin (%)

13.4% 11.3%

11.8% 11.2%

Rs. Crores

+17%

29.8

25.5

d e t a d

i l

o s n o C

H1 FY22

H1 FY23

H1 FY22

H1 FY23

CDMO

Trade Generics

Exports

+8%

202.1

186.9

+52%

44.5

29.2

7.7

-42%

4.5

e u n e v e R

a c i t r e V

H1 FY22

H1 FY23

H1 FY22

H1 FY23

H1 FY22

H1 FY23

Vertical Break-up

Q1FY23

Q2FY22

Q2FY23

80%

18%

CDMO Trade Generics & OTC Exports

79%

15%

80%

17%

CDMO Trade Generics & OTC Exports

H1FY22

H1FY23

83%

13%

80%

18%

CDMO

Trade Generics & OTC

Exports

CDMO

Trade Generics & OTC

Exports

Consolidated Profit & Loss Statement – Q2 & H1 FY23

Particulars (Rs. Crores)

Q2FY23

Q2FY22

YoY%

H1FY23

H1FY22

YoY%

Net Revenue from Operations

132.7

115.3

15.2%

COGS

Gross Profit

Gross Margin (%)

Employee Expenses

Other Expenses

EBITDA

EBITDA Margin (%)

Other Income

Finance Costs

Depreciation

Reported PBT

Taxes

Reported PAT

84.4

48.3

75.1

40.2

20.3%

252.7

160.9

91.8

226.2

146.4

79.8

11.7%

15.0%

36.4%

34.9%

154 bps

36.3%

35.3%

105 bps

17.7

14.5

16.1

15.0

12.0

13.2

34.4

27.6

29.8

31.2

23.1

25.5

16.8%

22.0%

12.1%

11.4%

67 bps

11.8%

11.3%

52 bps

2.6

0.1

2.9

15.6

3.4

12.2

1.2

0.4

3.1

10.9

43.9%

2.6

8.3

46.9%

5.5

0.5

5.7

29.2

7.2

22.0

1.9

0.9

6.1

20.4

5.4

15.0

42.8%

46.8%

EBITDA Adjustments for Q2 & H1 FY23

Q2FY23 EBITDA Adjustment (Rs. Crores)

13.2

6.1

2.0

2.7

2.5

16.1

Q2FY22 - Reported

Higher/Lower Sales Impact on Gross Margins

Gross Margin Improvement/ Reduction

Employee Benefit Expenses

Other Expenses

Q2FY23 - Reported EBITDA

H1FY23 EBITDA Adjustment (Rs. Crores)

25.5

9.3

2.7

3.2

4.5

29.8

H1FY22 - Reported

Higher/Lower Sales Impact on Gross Margins

Gross Margin Improvement/ Reduction

Employee Benefit Expenses

Other Expenses

H1FY23 - Reported EBITDA

Rewarding Shareholders

•

Promoters & Key Managerial Personnel will NOT participate in Buy Back

Buy Back Route:

• Open Market

•

Price upto Rs. 325

Particulars

Price Upto (per share)

INR

325

Buy Back to the extent of Rs. 25 Crs# as against Cash PAT* of Rs. 27.7 Crs for the H1 FY23

Buy Back amount taken from the profit generated during H1FY23 and NOT from IPO Proceeds

Buy Back Amount

Rs. 25 Crores#

Particulars

Cash PAT* for H1 FY23

Amount to be utilized for Buy Back

Net Cash Profit

Amount (in Rs. Crs)

Remarks

27.7

(25.0)

2.7

Investment, Cash & Bank (As on H1 FY23)

179.6

Available for future Inorganic Expansion

Net Worth (As on H1 FY23)

408.3

Robust Net Worth to support inorganic expansion through leverage, if required

# Excluding taxes *Cash PAT = PAT + Depreciation & Amortization

Consolidated Balance Sheet

Equities & Liabilities (Rs. Crores)

Sept-22

Mar-22

Equity

Equity Share capital

Other Equity

Non Controlling Interest

Total Equity

Financial liabilities

(i) Borrowings

(ii) Other Financial liabilities

(iii) Lease Liability

Deferred tax liabilities (Net)

Provisions

Total Non Current Liabilities

Financial liabilities

(i) Borrowings

(ii) Trade Payables

(iii) Other financial liabilities

(iv) Lease Liability

Provisions

Other current liabilities

Total Current Liabilities

10.9

397.4

0.0

408.3

0.3

0.0

1.1

0.0

1.8

3.2

0.4

78.6

23.6

0.8

0.4

3.0

106.7

10.9

383.9

0.0

394.8

0.4

0.2

0.0

1.6

2.2

5.7

63.2

22.7

0.5

0.3

1.5

94.0

Total Equity and Liabilities

518.2

491.0

Assets (Rs. Crores) Non Current assets Property, Plant and Equipment Capital work in progress Intangible assets Right to use assets Financial Assets

(i) Investments (ii) Other Financial Assets

Deferred Tax Assets (net) Other non-current assets Total Non Current Assets Current Assets Inventories Financial Assets

(i) Investments (ii) Trade receivables (iii) Cash and Bank Balances (iv) Bank Balances other than Cash & Cash Equivalent (v) Other Financial Assets

Current Tax Assets(Net) Other current assets Total Current Assets Non current Asset held for sale

Total Assets

Consolidated

Sept-22

Mar-22

85.0 13.6 1.0 3.6

0.0 3.1 2.2 5.4 113.9

82.2

79.0 105.3 22.0

78.6

5.1 3.1 29.2 404.3

88.4 7.6 0.9 2.3

0.0 5.2 2.0 3.0 109.4

58.7

64.8 110.8 0.6

113.2

4.2 4.1 25.3 381.7

518.2

491.0

Consolidated Cash Flow Statement

Particulars (Rs. crores)

H1FY23

H1FY22

Operating profit before working capital changes

Changes in working capital

Cash generated from Operations

Direct taxes paid (net of refund)

Net Cash from Operating Activities

Net Cash from Investing Activities

Net Cash from Financing Activities

Net Increase in Cash and Cash equivalents

Add: Cash & Cash equivalents at the beginning of the period

Cash & Cash equivalents at the end of the period

30.5

-3.3

27.2

-6.3

20.9

15.5

-15.1

21.3

0.6

21.9

27.4

4.7

32.0

-6.9

25.2

-72.5

132.6

85.3

15.9

101.2

Company Overview

Windlas Biotech at Glance

Scalability

Durability

Profitability

▪ Top 5 Domestic Formulations CDMO in terms

▪ Well aligned workforce with ESOPs

▪ Consistently maintained Gross Margins

of Revenue (CRISIL Report)

▪ License to manufacture 4,641* Products (as of

March, 2022) across 4 plants with 7bn+ Tablets/Capsules capacity

▪ 1 employee in Quality for every 3 employees in

Manufacturing (as of March 31, 2022)

▪ Provided CDMO services to 7 of the Top 10 (15 of top 20) Indian Pharmaceutical Formulations Companies (in FY22)

▪ Growing Trade Generics Business through

channel, product and geographic expansion.

▪ Digitalized Planning and Quality

Management Systems with Data Analytics based decision support

▪ Emphasis on Chronic and Sub-chronic therapies (58%) and Complex Generics (74%) (for FY22)

▪ Own R&D Labs High innovation velocity - Complex products grown from 934 to 1,325 in FY22 vs FY21

above 35% since FY19

▪ RoE** – 32.9% and RoCE** – 34.6% For

FY22

▪ PAT*** of INR 38.1 crores for FY22 with

8.2% PAT margin

▪ Net Debt Free Company.

*from the State Drug Licensing Authority, Drug Controlling and Licensing Authority (Manufacturing), Garhwal Mandal, Uttarakhand ** Capital Employed & Equity calculations for ROCE & ROE are after removing cash/bank & mutual fund balances | ***PAT here is Profit for the period/year before exceptional items

Windlas Biotech’s Presence in Pharma Value Chain

Research

Drug Development

API Manufacturing

Formulation Manufacturing

Packaging

Value Chain

CRO Vertical

CDMO Vertical

* Signifies Presence of Windlas Biotech in the Respective Verticals

Journey So Far…

▪ Commenced operations at

Dehradun Plant – I and initiated commercial production

Dehradun Plant – IV Revenues crossed INR 100 Crores for FY2010

▪ Received first USFDA inspection clearance for the WHC Plant Revenues crossed ₹200 Crores for the FY 2013-14 Commenced operations at Dehradun Plant – II

▪ Investment of ₹75 Crores from Tano

India Private Equity Fund II

2001

2010

2014

2015

2021 Onwards

▪ Approval of Scheme of

Amalgamation of Windlas Healthcare

▪ Capital expenditure of INR 79.18 Crores towards addition of Fixed Assets**

▪ Capacity of Capsules/ Tablets

increased from 5 Bn+ as of Mar 31,2020 to 7 Bn+ as of March 31, 2022

2020

2019

2018

▪ Capital Expenditure of INR 15.2 Crores towards addition to Fixed Assets** ▪ Acquired the erstwhile associate –

Windlas Healthcare

▪ Domestic Trade Generics Brands

revenue Crossed 30 Crores while the FY19-FY21 CAGR had grown by 27%

▪ Capital expenditure of INR 12

Crores towards addition to Fixed Assets **

• Revenues crossed ₹300 Crores for the FY 2016-17 • Launched first product in the United States from

the Dehradun Plant – IV

• Commenced operations at Dehradun Plant – III • Divestment of Windlas Healthcare to Cadila

Healthcare

** Fixed assets include property, plant & equipment and intangible assets (excluding CWIP/ROU/Intangible under development)

Strong Board of Directors…

▪ Chairman of Confederation of Indian

Industries , Uttarakhand State Council, ▪ Established Windlas Biotech in 2001. ▪ Led Windlas Biotech as MD till 2020

▪

▪ ▪

▪

13+ years of experience in field of management Bachelor’s degree from the IIT-BHU, MSc. in Material Science & Engr. from Georgia Institute of Technology and MBA from the Graduate School of Business, University of Chicago Set up our Domestic Trade Generics and Exports SBVs Leads the company since 2020 & plays a significant role in preparing strategy of Company

Co-founded Windlas Biotech in 2001 Deeply engaged in managing client relations, and product portfolio expansion Plays a significant role in driving the product portfolio decisions and overall commercial operations including business development, supply chain and procurement He is a BBA graduate from George State University Atlanta

Ashok Kumar Windlass Whole Time Director

Hitesh Windlass Managing Director

Manoj Kumar Windlass Jt. Managing Director

▪ 20+ years of experience in the

pharmaceutical industry, he has a Bachelor’s degree in Law from the Hemwati

▪ Nandan Bahuguna Garhwal University,

Srinagar (Garhwal)

▪ 20+ years of experience in manufacturing

and supply operations.

▪ Previously associated with ICI India Ltd, Baxter India Private Ltd, and Pfizer Ltd. ▪ Bachelor’s degree from IIT-B & Master’s degree in science from University of Kentucky

Pawan Sharma Executive Director

Vivek Dhariwal Chairman and Independent Director

▪ Bachelor’s degree in technology from the IIT,

Delhi, Master’s degree in science from University of Southern California, and an MBA from University of Chicago.

▪ Currently associated with Michael & Susan Dell Foundation India and previously with Boston Consulting Group

Prachi Jain Windlass Non-Executive Director

Srinivasan Venkatraman Non-Executive Director

▪ Fellow member of the Institute of Chartered Accountants of India. ▪ Previously associated with Wealth Tree Advisors, Hines, Aon Global Insurance Services, and Lovelock & Lewes

Gaurav Gulati Non-Executive Director

▪ Bachelor’s degree in Science (computer science) from the University of Illinois. MBA from Booth School of Business.

…Coupled with Proficient Management Team

Mr. Ashok Kumar Windlass, Whole Time Director Founded Windlass Biotech in 2001 20+ Years of Experience in the industry, he has led Windlas Biotech as MD till 2020.

Ms. Komal Gupta, Chief Financial Officer Previously worked with DSM Sinochem Pharmaceuticals India Private Limited and Anand Automotives Systems Ltd.

Mr. Hitesh Windlass, Managing Director 13+ Years of experience in field of management Leads the company since 2020 & plays a significant role in preparing strategy of Company.

Mr. Om Prakash Sule, Site Quality Head Experience - 24+ Years; Previously worked with Piramal Enterprises Limited and Mankind Pharma Limited.

Mr. Manoj Kumar Windlass, Joint Managing Director Co-founded Windlas Biotech in 2001. Deeply engaged in managing client relations, and product portfolio expansion

Mr. Ananta Narayan Panda , CS and Compliance Officer Experience - 20+ Yr; Previously worked with GMR Airports Limited, Spice Smart Solutions Limited

Mr. Pawan Sharma, Executive Director 20+ Years of experience in the industry. He has been attached with Windlass Since 2001. Controls the Administrative & Commercial activities of the company.

Mr. Mohammed Aslam, VP – Sales and Marketing Previously worked with Pharmed Private Limited, Life Medicare & Biotech Pvt Ltd, Modi Mundipharma Private Ltd and Life Medicare and Biotech Private Limited

Vertical Overview

CDMO

Trade Generics

Exports

▪

focused on providing CDMO vertical products & services across- a diverse range of pharmaceutical & nutraceutical generic products. Such products are sold to Indian or foreign Pharma MNCs who market products under their own brand names.

Contribution as a % of Total Revenue from Operations

84%

87%

85%

81%

▪

This vertical consists of Trade Generic Products which include Nutraceutical & Health Supplement products. These products are Drugs for which Patents have been expired and are typically used as a substitute to branded expensive Generic medicines. Generally sold to the Distributors & not Medical representatives.

Contribution as a % of Total Revenue from Operations

10%

13%

▪

Export vertical is engaged in identifying high growth opportunities in Semi regulated international markets & selected regulated markets. The motive is to Develop & Register product applications in order to obtain marketing authorizations for medicines & health supplements. Subsequently such products are sold to Pharmaceutical & Pharmacies in the respective markets.

Companies

Contribution as a % of Total Revenue from Operations

FY19

FY20

FY21

FY22

FY19

FY20

FY21

FY22

FY19

FY20

FY21

FY22

CDMO Business Highlights

No. Of Customers/ Buyers 285

Brand Used Brand of the end CDMO Customer

Products Fixed dosage, Fixed dosage plus modified release, Customized generics, chewable/ dispersible and plain oral solids

Revenue Mix (% of FY22) 81%

Amongst the Top 5* in India

Stand amongst the Top 5 Domestic Formulations CDMO in India

* Source: CRISIL

Well Diversified Product Portfolio

Windlas provides CDMO services & products ranging from product discovery, product development, licensing and commercial manufacturing of complex generic products in compliance with current GMP

Company’s product portfolio predominantly overlaps with Fast Growing Chronic segment and High Margin Complex Generic Vertical:

CDMO Revenue grew with a CAGR of 14%

Value chain of End-to-end Services

INR Crores

+14%

362

380

257

287

Product Discovery & Development

Portfolio Bifurcation as % of Total Revenue from Operations FY22

25%

42%

58%

FY19

FY20

FY21

FY22

74%

CDMO Revenue

No. of CDMO Products Catered every year

Chronic & Sub-Chronic Acute

Complex Generics Conventional Products Others

+18%

1,464

1,051

1,117

900

(i) chronic and sub-chronic, such as, anti-diabetic, cardiovascular, neuropsychiatry, respiratory health and nutraceuticals ; and (ii) acute, such as, gastroenterology, vitamins, minerals and supplements (“VMS”), analgesic, dermatological and cough/ cold

2019

2020

2021

2022

Licensing

Contract Manufacturing

Niche Value added Proposition: Through entry into Injectables

Large Marquee Customer Base

✓ Streamlined Client Acquisition Process

Added New Customers at a rapid pace

Lead Identification

Proposal Creation

Negotiation

Contract Winning

Client Management

✓ Key Factors that lead to Expansion of Customer base

Audits by several MNC & Domestic Customers over the years

Product Excellence : dosage innovation, developing complex generic products

Manufacturing Excellence : track record, responsiveness, quality & technical standards, turnaround times

Planned capital expenditure: Invested in specialized services and equipment and dedicated infrastructure

✓ Key Factors that lead to Expansion of Customer base

▪ Quality, Quantity and specifications for the products

▪ Company is responsible for the procurement of raw materials and packaging

materials

▪ Provide the proper pricing & supply terms

285

+43%

204

143

FY19

FY20

FY21

FY22

No. of CDMO Customers catered to

Key Highlights

We have consistently maintained strong, exclusive & Long-Standing relationships with the leading Indian Pharmaceutical companies.

Provided CDMO Services to 7 of the top 10 (15 of the top 20) Indian Formulations pharmaceutical companies.

De-Risking the Customer Concentration

Long-term nature of the relationships help in pre-plan the Capex and eventually help in achieving sustainable growth and profitability

Long-term Relationships with Marquee Clients

Ease is Pre-Planning Capex

Increased Economies of Scale

Strengthened Purchasing Power for Raw Materials

Competitive cost structure in order to achieve Profitability

Continuously reducing highest customer’s contribution

Consistently maintained the exposure to top 10 customers below 60%

12.3%

11.7%

12.6%

11.0%

57.0%

57.1%

57.9%

51.9%

2019

2020

2021

2022

2019

2020

2021

2022

Scalability In CDMO Provides Growth Visibility

Globally 1/3rd of the R&D is outsourced to CDMO companies in formulations segment & India is emerging as a key player in CDMO Vertical

Key reasons for Outsourcing by Pharma companies

Significant R&D spends to continue to boost pharmaceutical growth across major markets

Flexibility and reduced costs in the business models of large Pharma companies

Growing Demand for Generics & Biologics

Rise in amount of drug approvals

End to end service and Technical specialties of contract manufacturers

Increase in off-patent products to aid outsourcing segment

USD Billion

R&D Expenditure

1,053

1,142

1,188

+5%

1,237

1,297

1,680

CAGR 5%

2016

2017

2018

2019

2020

2025P

~75 to 80% of R&D spending in the biopharmaceutical industry can be outsourced

USD Billion

R&D Outsourced

India has a proven track record in Outsourcing because of

+7%

CAGR 8%

Cost effectiveness

Technical Expertise

Infrastructure

Source: CRISIL Report

2016

2017

2018

2019

2020

2025P

Underpinned by Strong Tailwinds for Organized Players

Key Updates in CDMO industry

Scaled CDMOs shifting identity from “Supplier” to “Partner”

Customers asking for higher quality systems in R&D as well as manufacturing

CDMOs deploying superior R&D infrastructure, expertise and capital

‘Marketeers’ equally responsible for quality of the drug product in eyes of regulator

New schedule M to be implemented in October 2021 – many small manufacturers may become unviable

Production Linked Incentive - 2 Scheme to cover complex products in formulations

‘Raw materials purchase efficiency of larger CDMOs exceeds that of customers in many small – mid volume products

Demand from customers for launch of patent expiry products

End to end services offered by larger CDMO reduces the complexities in inventory management & logistics for the big pharma companies

Strong Industry Tailwind- Domestic Formulations CDMO to grow at 14%+ CAGR in next 5 years

Consolidation in the CDMO industry driven by need for providing better and wider portfolio of services

INR 370-410 Billion FY25P

~14% CAGR

INR 250 Billion FY21P

FY20

~400 Organised + 15,000 Unorganised Players 79%

Top 6 (incl. Windlas Biotech) 21%

Source: CRISIL Report

Capex & Outlook For Injectables

Key Highlights

▪ Planned Rs. 50 Crores

Capex

▪ Brown Field Project at Dehradun Plant - II

▪ Liquid Vials & Lyophilized

vials

Multiple Triggers for Revenue Growth and Improved Return Ratios

Key Growth Drivers

Impact

▪ Rise in chronic diseases ▪ Emergence of New Drug

Delivery Systems

▪ New Therapeutic areas for

Injectables

▪ Would help improve economies of scale ▪ B2B Injectables CDMO

vertical to improve overall company’s margins

Foray into High Growth Injectables Business: Injectables business will complement the existing CDMO offerings and will enable to achieve higher margins

Outlook on Global Injectables Market

Outlook on Domestic Injectables CDMO Industry

$ 700-800 Billion 2025P

~8% CAGR

$ 502 Billion 2020

Source: CRISIL Report

~INR 51 Billion FY25P

~12% CAGR

~INR 32 Billion FY21P

Industry Outlook

✓ Our product portfolio predominantly overlaps with Fast Growing Chronic segment and High Margin Complex Generic Vertical. ✓ Chronic Therapies and Oral Solids to dominate their respective categories for the next 5 years, in formulations segment

Chronic therapies to continue to account for a higher share of the domestic formulations CDMO market

Market share as of FY20

46.5%

25.0%

15.0%

6.0%

7.5%

Anti-Diabetic

Cardiac

Dermatology

Respiratory

Others

Market share as of FY25P

27.0%

43.0%

15.0%

5.0%

8.0%

Anti-Diabetic

Cardiac

Dermatology

Respiratory

Others

Oral solids expected to continue to account for more than 2/3rd share of the domestic formulations CDMO market

Market share as of FY20

3.0%

13.0%

13.8%

70.3%

Solids

Injectables

Liquids

Others

Market share as of FY25P

2.8%

13.0%

13.7%

70.5%

Solids

Injectables

Liquids

Others

Domestic Trade Generics Business Overview

No. Of Customers/ Buyers 856 Stockists & Distributors (Served during FY22)

Brand Used Company’s Brand Names

Products Nutritional, Ayurvedic, Wellness & Personal Care

Revenue Mix (% of FY22) 13%

No. of Brands 218

Leveraging Trade Generics Market Opportunity

Highlights

Key Drivers

Fastest Growing SBV in the last three years chart

Rs. 61 Crores Trade Generics SBV revenue (FY22)

Low costs generics

compared to branded

INR Crores

Trade Generics Revenue

+31%

Distributed through 856 Stockists & Distributors

Similar quality to branded generics but are sold at relatively lower prices

FY19

FY20

FY21

FY22

Sold directly to the distributor and not marketed through Medical representatives

People in rural areas who are less privileged to access the healthcare facilities

With number of Brands on growing at a healthy pace

+26%

185

218

Stockists and distributors spread across 14 states (FY22)

Government push for schemes such as Jan Aushadhi Yojana, encouraging traded generics use

110

128

FY19

FY20

FY21

FY22

Export Business Overview

No. Of Customers/ Buyers Focused on Emerging & Semi-Regulated Markets

Brand Used Own Brands and End Customer Brands

Products Exported 68 Products during FY22 which includes Generic Medicines & Health Supplements

Revenue Mix: 4.5% of FY22 Revenue from Operations Exports SBV: INR of 21 crore as of FY22. This vertical saw a 10.2% growth YoY for FY22.

Geographic Reach

Robust R&D Capabilities

Robust R&D capabilities help in Customize and Market Complex; Generic Products to Customers and differentiate from Competition

R&D Key Highlights

Licensed to manufacture 4,641 Products as of FY22

5 out of 9 filed Patents were granted as of FY22

41 Experts in Medical Affairs As of FY22

Focus on low cost First-to-launch generic products

Significant Experience in developing Multi-Drug Products

Consistent in R&D Expenditure

Robust Growth in Complex Generics

INR Crores

R&D Expenditure

No. of Variations in Complex Generics

+16%

6.5

4.2

3.9

3.6

625

725

+28%

934

1,325

2019

2020

2021

2022

Leading to New Innovations

2019

2020

2021

2022

Leading to Significant increase in Revenue from High Margin Complex Generics:

Chocolate flavored chewable tablets

28%

29%

33%

35%

Dispersible tablets

Sustained release products

Novel Formulations of Existing Molecules

29%

11%

32%

28%

11%

30%

24%

12%

31%

25%

12%

26%

Fixed Dosage Combinations

Fixed Dosage Modified Release

Customised Generics

Chewable/ Dispersable

Plain Oral Solids

FY19

FY20

FY21

FY22

Competencies in Manufacturing Facilities

Efficiency & Effectiveness in Regulatory & Quality Compliance act as solid Entry Barriers

Dehradun Plant 1 commenced operations in 2001

Dehradun Plant 2 commenced operations in 2014

Dehradun Plant 3 commenced operations in 2018

Dehradun Plant 4 commenced operations in 2009

Total Installed operating capacity per annum

Plant wise operating capacity as of 31st March FY22

Key Highlights

Windlas Biotech Limited has informed the Exchange about Investor Presentation

Market Movers